Endothelin 1 swine, human
(Synonyms: 内皮缩血管肽 1 (猪,人)) 目录号 : GC30485
内皮素 1（猪、人）是一种 21aa 肽血管收缩剂和内皮素 (ET) 受体 ETA 和 ETB 的激动剂（IC50 分别 = 0.15 和 0.12 nM）。
Cas No.:117399-94-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
Immortalized mouse podocytes |
|
Preparation Method |
Immortalized mouse podocytes were incubated with RPMI 1640 medium alone or with 100 nM Endothelin 1 (swine, human) for 5, 15, or 30 minutes. |
|
Reaction Conditions |
100 nM for 5, 15, 30 minutes, 16, 24 hours. |
|
Applications |
Endothelin 1 (swine, human) reduced synaptopodin and increased a-SMA expression at 6 hours and even more so at 24 hours |
| Animal experiment [2]: | |
|
Animal models |
Male severe combined immunodeficiency (SCID) mice |
|
Preparation Method |
The mice were inoculated with PPC-1 (4×105 cells/25 µl/paw) subcutaneously in the left paw using a microsyringe. After acclimation, 10 µl of vehicle alone or vehicle with Endothelin 1 (swine, human) (10 pmol/paw) or sarafotoxin S6c was subcutaneously injected into the left hind paw. |
|
Dosage form |
10 pmol/paw, s.c. |
|
Applications |
Endothelin 1 (swine, human) (10 pmol/paw) induced pain responses in the sham-operated animals and potentiated responses in the PPC-1 inoculated animals |
|
References: [1]: Buelli S, RosanÒ L, Gagliardini E, et al. β-Arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury[J]. Journal of the American Society of Nephrology, 2014, 25(3): 523-533. |
|
Endothelin 1 (swine, human) is a 21aa peptide vasoconstrictor and agonist of endothelin (ET) receptors ETA and ETB (IC50s = 0.15 and 0.12 nM, respectively) [1]. Endothelin 1 (swine, human) is the endothelin generated in the endothelium, where it acts in a paracrine or autocrine manner on ETA and ETB receptors on adjacent endothelial or smooth muscle cells [2].
Endothelin 1 (swine, human) activats endothelin-A receptor (ETAR) and drives epithelial-to-mesenchymal transition in ovarian tumor cells through b-arrestin signaling. In cultured mouse podocytes, Endothelin 1 (swine, human) caused loss of the podocyte differentiation marker synaptopodin and acquisition of the mesenchymal marker a-smooth muscle actin. Endothelin 1 (swine, human) promoted podocyte migration via ETAR activation and increased b-arrestin-1 expression [3].
The Endothelin 1 (swine, human) (1nmol/kg) produced strong pressor responses in the anesthetized rats in vivo [4]. Mice received an intradermal injection of 1-30 pmol Endothelin 1 (swine, human) and were caused dose-dependent scratching bouts [5]. A subpressor dose of ET-1 administered to rats was found to increase glomerular permeability and inflammation as well as the excretion of the glomerular slit-diaphragm protein nephrin, effects that could be blocked by an ETA receptor antagonist [6]. The magnitude of the ET-1 rise during antiangiogenic treatment may be useful biomarker of the efficacy of treatment [7].
References:
[1]. Kikuchi T, Kubo K, Ohtaki T, et al. Endothelin-1 analogues substituted at both position 18 and 19: highly potent endothelin antagonists with no selectivity for either receptor subtype ETA or ETB[J]. Journal of medicinal chemistry, 1993, 36(25): 4087-4093.
[2]. Schiffrin E L. Role of endothelin-1 in hypertension and vascular disease[J]. American journal of hypertension, 2001, 14(S3): 83S-89S.
[3]. Buelli S, Rosanò L, Gagliardini E, et al. β-Arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury[J]. Journal of the American Society of Nephrology, 2014, 25(3): 523-533.
[4]. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes[J]. Proceedings of the national academy of sciences, 1989, 86(8): 2863-2867.
[5]. Trentin P G, Fernandes M B, D'Orléans-Juste P, et al. Endothelin-1 causes pruritus in mice[J]. Experimental biology and medicine, 2006, 231(6): 1146-1151.
[6]. Saleh M A, Pollock J S, Pollock D M. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease[J]. Journal of Pharmacology and Experimental Therapeutics, 2011, 338(1): 263-270.
[7]. Lankhorst S, Jan Danser A H, van den Meiracker A H. Endothelin-1 and antiangiogenesis[J]. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2016, 310(3): R230-R234.
内皮素 1（猪、人）是一种 21aa 肽血管收缩剂和内皮素 (ET) 受体 ETA 和 ETB 的激动剂（IC50 分别 = 0.15 和 0.12 nM）[1]。内皮素 1（猪、人）是在内皮细胞中产生的内皮素,它以旁分泌或自分泌的方式作用于相邻内皮细胞或平滑肌细胞上的 ETA 和 ETB 受体[2]。
内皮素 1（猪、人）激活内皮素 A 受体 (ETAR) 并通过 b-arrestin 信号传导驱动卵巢肿瘤细胞的上皮-间质转化。在培养的小鼠足细胞中,内皮素 1（猪、人）导致足细胞分化标志物突触蛋白的丢失和间充质标志物 a-平滑肌肌动蛋白的获得。内皮素 1（猪、人）通过 ETAR 激活促进足细胞迁移并增加 b-arrestin-1 表达[3]。
内皮素 1（猪、人）(1nmol/kg) 在麻醉大鼠体内产生强烈的升压反应 [4]。小鼠皮内注射 1-30 pmol 内皮素 1（猪、人）并引起剂量依赖性抓挠发作 [5]。研究发现,给大鼠施用降压剂量的 ET-1 可增加肾小球通透性和炎症以及肾小球裂隙隔膜蛋白肾素的排泄,这些作用可被 ETA 受体拮抗剂阻断[6]。抗血管生成治疗期间 ET-1 升高的幅度可能是治疗疗效的有用生物标志物[7]。
| Cas No. | 117399-94-7 | SDF | |
| 别名 | 内皮缩血管肽 1 (猪,人) | ||
| Canonical SMILES | Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp (Disulfide bridge: Cys1-Cys15, Cys3-Cys11) | ||
| 分子式 | C109H159N25O32S5 | 分子量 | 2491.9 |
| 溶解度 | H2O : 1.8 mg/mL (0.72 mM; ultrasonic and adjust pH to 3 with HCl) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.4013 mL | 2.0065 mL | 4.013 mL |
| 5 mM | 0.0803 mL | 0.4013 mL | 0.8026 mL |
| 10 mM | 0.0401 mL | 0.2007 mL | 0.4013 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Hyperglycemia Augments Endothelin-1-Induced Constriction of Human Retinal Venules
Purpose: Endothelin-1 (ET-1) is a potent vasoactive factor implicated in development of diabetic retinopathy, which is commonly associated with retinal edema and hyperglycemia. Although the vasomotor activity of venules contributes to the regulation of tissue fluid homeostasis, responses of human retinal venules to ET-1 under euglycemia and hyperglycemia remain unknown and the ET-1 receptor subtype corresponding to vasomotor function has not been determined. Herein, we addressed these issues by examining the reactivity of isolated human retinal venules to ET-1, and results from porcine retinal venules were compared. Methods: Retinal tissues were obtained from patients undergoing enucleation. Human and porcine retinal venules were isolated and pressurized to assess diameter changes in response to ET-1 after exposure to 5 mM control glucose or 25 mM high glucose for 2 hours. Results: Both human and porcine retinal venules exposed to control glucose developed similar basal tone and constricted comparably to ET-1 in a concentration-dependent manner. ET-1-induced constrictions of human and porcine retinal venules were abolished by ETA receptor antagonist BQ123. During high glucose exposure, basal tone of human and porcine retinal venules was unaltered but ET-1-induced vasoconstrictions were enhanced. Conclusions: ET-1 elicits comparable constriction of human and porcine retinal venules by activation of ETA receptors. In vitro hyperglycemia augments human and porcine retinal venular responses to ET-1. Translational relevance: Similarities in vasoconstriction to ET-1 between human and porcine retinal venules support the latter as an effective model of the human retinal microcirculation to help identify vascular targets for the treatment of retinal complications in patients with diabetes.
Endothelin-1 regulates oligodendrocyte development
In the postnatal brain, oligodendrocyte progenitor cells (OPCs) arise from the subventricular zone (SVZ) and migrate into the developing white matter, where they differentiate into oligodendrocytes and myelinate axons. The mechanisms regulating OPC migration and differentiation are not fully defined. The present study demonstrates that endothelin-1 (ET-1) is an astrocyte-derived signal that regulates OPC migration and differentiation. OPCs in vivo and in culture express functional ET(A) and ET(B) receptors, which mediate ET-1-induced ERK (extracellular signal-regulated kinase) and CREB (cAMP response element-binding protein) phosphorylation. ET-1 exerts both chemotactic and chemokinetic effects on OPCs to enhance cell migration; it also prevents lineage progression from the O4(+) to the O1(+) stage without affecting cell proliferation. Astrocyte-conditioned medium stimulates OPC migration in culture through ET receptor activation, whereas multiphoton time-lapse imaging shows that selective ET receptor antagonists or anti-ET-1 antibodies inhibit OPC migration from the SVZ. Inhibition of ET receptor activity also derepresses OPC differentiation in the corpus callosum in slice cultures. Our findings indicate that ET-1 is a soluble astrocyte-derived signal that regulates OPC migration and differentiation during development.
Human polymorphonuclear leukocytes have dual effects on endothelin-1: the induction of endothelin-1 mRNA expression in vascular endothelial cells and modification of the endothelin-1 molecule
The effect of human polymorphonuclear leukocytes (PMNs) on the expression of the endothelin-1 (ET-1) gene and the production of ET-1 peptide was investigated. Human PMNs were separated from venous blood with Mono-Poly Resolving Medium and activated by incubation with formyl-methionyl-lencylphenylalanine (FMLP) (1 microM). Then PMN suspension was added to cultured porcine endothelial cell monolayers and coincubated for various periods. Following the coincubation, ET-1 mRNA in endothelial cells was examined by Northern blotting and immunoreactive ET-1 (irET-1) peptide levels in the conditioned media were measured by an enzyme-linked immunosorbent assay (ELISA). Similar experiments were also carried out with cell-free PMN supernatant. Untreated and activated PMNs led to a 1.4-fold and 6.3-fold increase in ET-1 mRNA levels in endothelial cells, respectively, at 6h, while irET-1 peptide levels did not significantly increase as compared with control. In contrast, when PMNs were coincubated in the presence of an Intercell chamber without direct contact to endothelial cells, PMNs did not induce ET-1 mRNA expression in endothelial cells, and significantly decreased irET-1 peptide levels in the conditioned media. Cell-free PMN supernatant did not have all these effects on ET-1. These findings suggest that direct PMN-endothelial cell contact was essential for PMN-induced expression of the ET-1 gene and that PMNs may decrease irET-1 through some modification of the ET-1 molecule.
Localisation of endothelin-1 mRNA expression and immunoreactivity in the retina and optic nerve from human and porcine eye. Evidence for endothelin-1 expression in astrocytes
We have investigated the localisation of endothelin-1 (ET-1) mRNA and ET-1-like immunoreactivity in retina and anterior portion of optic nerve from human and porcine eyes. In situ hybridisation method revealed expression of ET-1 mRNA mainly in the innermost layers of the retinas, in the retinal pigment epithelium cells as well as in the astrocytes of the optic nerve. Immunohistochemical studies showed that ET-1-like immunoreactivity appeared in the same regions where ET-1 mRNA was expressed as well as in the inner nuclear layer and in the inner segments of photoreceptors. In the nerve fibre and ganglion cell layers, astrocytes expressed both glial fibrillary acidic protein and ET-1 proteins suggesting that these cells may secrete ET-1. Expression of ETA and ETB receptors in human retina were demonstrated by reverse transcription-polymerase chain reaction. Our results demonstrated expression of ET-1 in glial, neural and vascular components of retina and optic nerve from human and porcine eyes.
Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells
We examined the effect of human recombinant interleukin 1 (IL-1) on the production of endothelin-1 by cultured porcine endothelial cells. The induction of endothelin-1 mRNA began within 1 hr of exposure to IL-1, showed twin peaks at 4 and 24 hr, and declined thereafter. Enzyme-linked immunosorbent assay revealed that the amount of endothelin-1 peptide in conditioned media was also increased by IL-1 in a dose- and time-dependent manner. Our results suggested that IL-1, a macrophage-derived cytokine, may affect the contraction and proliferation of vascular smooth muscle cells by stimulating the production of endothelin by endothelial cells.